Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Date: May 27, 2020
Company: Arcus Biosciences, Inc. (RCUS)
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities with Gilead Sciences, Inc.
Key Financial Metrics and Transaction Terms
This filing details a strategic collaboration and investment rather than standard periodic financial results. Key financial terms include:
- Upfront Cash Payment: $175 million from Gilead to Arcus.
- Equity Investment: $200 million upfront purchase of 5,963,029 shares of Arcus common stock at $33.54 per share.
- Option Fees: Ranging from $200 million to $275 million per program for current clinical programs; $150 million for future programs entering clinical development.
- Regulatory Milestones: Up to $500 million potential U.S. regulatory approval milestones for the TIGIT program (AB154).
- R&D Support: Up to $400 million in ongoing research and development support from Gilead over the collaboration term.
- Royalties: Tiered royalties ranging from the high teens to low twenties percent of revenues on optioned programs.
Material Changes and Strategic Shifts
The filing represents a significant strategic shift through the following agreements:
- Collaboration Agreement: Gilead obtains an exclusive option to acquire an exclusive license to all of Arcus's current and future clinical programs for a 10-year term (plus up to 3 years for programs in clinical development).
- Immediate License: Gilead immediately obtained an exclusive license to Arcus's zimberelimab program upon the upfront payment.
- Profit Sharing: For optioned programs, companies will co-develop, equally share global development costs, and equally share profits and losses in the U.S.
- Commercial Rights: Gilead holds exclusive commercialization rights outside the U.S.; Arcus retains an option to co-promote in the U.S.
- Board Representation: Gilead has the right to designate two individuals to Arcus's Board of Directors.
Outlook, Risks, and Contingencies
- Future Equity Purchases: Gilead has the option to purchase additional shares over the next five years, up to a maximum of 35% of Arcus's then-outstanding voting common stock, at a price equal to the greater of a 20% premium to market or the initial purchase price.
- Termination Rights: The agreement may be terminated by either party for uncured material breach or insolvency, or by Gilead with sufficient prior written notice.
- Regulatory Review: The transaction is subject to review under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions.
- Expense Caps: Arcus's spending is subject to expense caps and true-up adjustments.
Investor Verification Checklist
- Verify the closing of the $175 million upfront cash payment and the $200 million equity investment.
- Confirm the status of the Hart-Scott Rodino Antitrust Improvements Act review.
- Review the full text of the Collaboration Agreement and Equity Agreements filed as exhibits to the Form 10-Q for the quarter ending June 30, 2020.
- Monitor the exercise of Gilead's option to acquire licenses for specific clinical programs and the associated option fees.
- Assess the impact of the 35% equity purchase option on future dilution and Arcus's capital structure.